Phase 2 clinical pharmacology study of TAP-144-SR (6M) in no treatment patients with Prostate Cancer
Latest Information Update: 04 Nov 2016
Price :
$35 *
At a glance
- Drugs Leuprorelin (Primary) ; Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Takeda
- 07 Jun 2016 New trial record